Literature DB >> 31514981

XingNaoJing injections protect against cerebral ischemia/reperfusion injury and alleviate blood-brain barrier disruption in rats, through an underlying mechanism of NLRP3 inflammasomes suppression.

Xiao-Yu Qu1, Yue-Ming Zhang1, Li-Na Tao1, Huan Gao1, Jing-Hui Zhai1, Jing-Meng Sun1, Yan-Qing Song2, Si-Xi Zhang3.   

Abstract

The aim of this study was to explore the neuroprotective effect and mechanism of XingNaoJing injections (XNJ) on cerebral ischemia injury and blood-brain barrier (BBB) disruption. Middle cerebral artery occlusion (MCAO) method was applicated to establish the model of cerebral ischemia/reperfusion (I/R) injury in rats. BBB permeability after I/R injury was assessed with the leaking amount of Evans Blue and the expression of occludin and ZO-1. The expression of NOD-like receptor family, pyrin domain containing (NLRP3) was checked to explore the inhibition of inflammation by XNJ. The results showed that XNJ could significantly increase the survival percent, decrease the infarct area and ameliorate neurological deficits and brain damage after I/R injury. Leaking amount of Evans Blue was reduced by XNJ, and the expression of tight junction protein, occludin and ZO-1 was also up-regulated by XNJ, which showed a role of protection on BBB disruption. The expression of NLRP3 was inhibited after exposure of XNJ, which was associated with inhibition of the inflammatory response. In summary, XNJ could suppress NLRP3 inflammasomes and improve BBB disruption and brain damage in rats after cerebral I/R injury, which provided a beneficial insight to further explore XNJ.
Copyright © 2019 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood-brain barrier; Cerebral ischemia/reperfusion injury; NLRP3 inflammasomes; XingNaoJing injections

Mesh:

Substances:

Year:  2019        PMID: 31514981     DOI: 10.1016/S1875-5364(19)30071-8

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  10 in total

Review 1.  NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia-Reperfusion Injury.

Authors:  Lixia Wang; Wei Ren; Qingjuan Wu; Tianzhu Liu; Ying Wei; Jiru Ding; Chen Zhou; Houping Xu; Sijin Yang
Journal:  Front Mol Neurosci       Date:  2022-05-06       Impact factor: 6.261

2.  Uncovering the Mechanism of the Xingnaojing Injection against Ischemic Stroke Using a Combined Network Pharmacology Approach and Gut Microbiota Analysis.

Authors:  Ganlu Liu; Jingfeng Lin; Lina Zhang; Qiang Gao; Zhenyi Wang; Ze Chang; Ying Gao; Dayong Ma; Zhenyun Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-20       Impact factor: 2.650

Review 3.  Pyroptosis in stroke-new insights into disease mechanisms and therapeutic strategies.

Authors:  Xue Gou; Dan Xu; Fengyang Li; Kai Hou; Weirong Fang; Yunman Li
Journal:  J Physiol Biochem       Date:  2021-05-04       Impact factor: 4.158

Review 4.  The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.

Authors:  Dan Zhang; Bing Zhang; Jin-Tao Lv; Ri-Na Sa; Xiao-Meng Zhang; Zhi-Jian Lin
Journal:  Pharmacol Res       Date:  2020-05-05       Impact factor: 7.658

5.  Maf1 Ameliorates Sepsis-Associated Encephalopathy by Suppressing the NF-kB/NLRP3 Inflammasome Signaling Pathway.

Authors:  Shenglong Chen; Chaogang Tang; Hongguang Ding; Zhonghua Wang; Xinqiang Liu; Yunfei Chai; Wenqiang Jiang; Yongli Han; Hongke Zeng
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

6.  Efficacy and Safety of Xingnaojing Injection for Emergency Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Liuding Wang; Xueming Fan; Yifan Chen; Xiao Liang; Wei Shen; Yunling Zhang
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

Review 7.  The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets.

Authors:  Rongrong Bai; Yue Lang; Jie Shao; Yu Deng; Reyisha Refuhati; Li Cui
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

8.  The expression and clinical significance of miRNA-183 in cerebral ischemia-reperfusion injury patients with cerebral small vessel disease.

Authors:  Zigen Liao; Hui Sun; Yanqun Chang; Hui Chen
Journal:  Ann Transl Med       Date:  2020-08

9.  Comprehensive Analysis of RNA Expression Profile Identifies Hub miRNA-circRNA Interaction Networks in the Hypoxic Ischemic Encephalopathy.

Authors:  Lin Wei; Xia Li; Lijuan Wang; Yanyan Song; Hongmei Dong
Journal:  Comput Math Methods Med       Date:  2021-09-21       Impact factor: 2.238

10.  Network pharmacology to investigate the pharmacological mechanisms of muscone in Xingnaojing injections for the treatment of severe traumatic brain injury.

Authors:  Zhuohang Liu; Hang Li; Wenchao Ma; Shuyi Pan
Journal:  PeerJ       Date:  2021-07-20       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.